Krystal Biotech (KRYS) Long-Term Debt Issuances (2017)
Krystal Biotech's (KRYS) quarterly Long-Term Debt Issuances came in at $999000.0 in Q2 2017, up 233.0% quarter-over-quarter from $300000.0 in Q1 2017.
Powered by 
Analysis
Krystal Biotech (KRYS) Long-Term Debt Issuances (2017) Analysis & Trends
Krystal Biotech has disclosed Long-Term Debt Issuances across 1 years of filings, most recently posting $999000.0 for Q2 2017.
- In Q2 2017, Long-Term Debt Issuances changed N/A year-over-year to $999000.0; the TTM figure through Dec 2017 stood at $1.3 million (changed N/A YoY), while the FY2017 annual figure was $1.3 million, up 13.45% from the prior year.
- Long-Term Debt Issuances came in at $999000.0 for Q2 2017 at Krystal Biotech, up from $300000.0 in the prior quarter.
- In the past five years, Long-Term Debt Issuances ranged from a high of $999000.0 in Q2 2017 to a low of $300000.0 in Q1 2017.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Long-Term Debt Issuances (Qtr) |
|---|---|---|---|---|---|
| 1 | Krystal Biotech | 10.22 Bn | 9.37 Bn | 112.79 Mn | - |
| 2 | CRISPR Therapeutics AG | 5.02 Bn | 5.02 Bn | - | - |
| 3 | Iovance Biotherapeutics | 3.68 Bn | 3.38 Bn | 55.72 Mn | - |
| 4 | Legend Biotech | 3.64 Bn | 2.68 Bn | 251.50 Mn | - |
| 5 | uniQure | 3.01 Bn | 3.01 Bn | 5.49 Mn | - |
| 6 | Beam Therapeutics | 2.54 Bn | 2.54 Bn | - | - |
| 7 | Precigen | 2.37 Bn | 2.37 Bn | 52.17 Mn | - |
| 8 | Sarepta Therapeutics | 2.26 Bn | 1.46 Bn | 251.87 Mn | - |
| 9 | Vericel | 1.98 Bn | 1.82 Bn | 56.40 Mn | - |
| 10 | Taysha Gene Therapies | 1.90 Bn | 1.90 Bn | - | - |